Novartis And UK Launch Partnership On Groundbreaking Cardiovascular Prevention Trial

Uses World-First Population Health Model

Partnership includes provision for fast-tracked uptake of inclisiran in England, if NICE finds it cost effective.

Ariel view of Novartis's new UK headquarters in White City, west London

A new partnership between Novartis AG and the UK government has been launched, to tap into the country’s expertise in clinical trials and healthcare data, and to prove the value of Novartis’ next blockbuster-in-waiting, cardiovascular treatment inclisiran.

The Swiss big pharma company acquired the RNA interfering therapy along with its developer The Medicines Company for $9.7bn last...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

17 Jul 2025

• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

17 Jul 2025

• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.